Leqembi, the newly-approved drug that can slow the progression of Alzhemier’s disease, will cost Medicare billions each year, according to an analysis from KFF. The analysis, published July 6, compared how much the drug could cost the program, based on uptake rate. The FDA approved the drug July 6. Medicare will cover the drug for […]